ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Rodney J. Hicks(Flinders Medical Centre), Christos Toumpanakis, Jarosław B. Ćwikła, Lisa Bodei(European Institute of Oncology), Gregory Kaltsas(National and Kapodistrian University of Athens), John Ramage(Hampshire Hospitals NHS Foundation Trust), Eva Tiensuu Janson(Uppsala University), Philippa Davies(The Royal Free Hospital), Dieter Hörsch(Philipps University of Marburg), Simona Grozinsky‐Glasberg(Hebrew University of Jerusalem), Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Ivan Borbath, Rudolf Arnold(Philipps University of Marburg)
Neuroendocrinology
January 1, 2017
10.1159/000475526
Cited by 331

Related Papers

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869